[From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time].
The worldwide use of fluoroquinolones in community and hospital settings, due to their high efficacy and tolerability, to the wide antibacterial spectrum and to the availability of an oral formulation, has created a relevant selective pressure for the emergence of resistant bacterial strains towards this antimicrobial class. Nevertheless, twenty years after development of first fluoroquinolones (e.g. norfloxacin and ciprofloxacin) and ten years after levofloxacin introduction, the antibacterial activity of these drugs remains, on the whole, high.
Rossolini
Gian Maria
GM
Dipartimento di Biologia Molecolare, Sezione di Microbiologia, Universita di Siena, Italy.
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy; D001424:Bacterial Infections / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects; D024841:Fluoroquinolones / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones